文献速递认知障碍与痴呆

甘特尼单抗与索拉尼单抗在显性遗传性阿尔茨海默病DIAN-TU-001试验中的淀粉样蛋白相关影像学异常:来自一项试验的经验教训

Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
PubMed 文献 · Ann Neurol · 2022-10-13

在显性遗传性阿尔茨海默病(DIAD)突变携带者中,142人分别接受甘特尼单抗皮下注射(n=52)、索拉尼单抗静脉注射(n=50)或安慰剂(n=40),评估淀粉样蛋白相关影像学异常(ARIA)。多数ARIA-E在影像学上可逆,通常无症状。

要点

  • 甘特尼单抗剂量超过225 mg时ARIA-E风险增加,APOE-ɛ4携带者及基线微出血者风险更高。
  • 多数ARIA-E在调整剂量后影像学可逆,通常无症状,未显著增加试验中止的几率。

核心结论

  • 在显性遗传性阿尔茨海默病中,索拉尼单抗与ARIA无关;甘特尼单抗剂量超过225 mg增加ARIA-E风险,APOE-ɛ4阳性或基线微出血者风险进一步增加;多数ARIA-E在影像学上可逆,通常无症状,未增加试验中止风险。

研究设计与样本

  • DIAN-TU-001试验中142例显性遗传性阿尔茨海默病突变携带者接受甘特尼单抗皮下注射(n=52)、索拉尼单抗静脉注射(n=50)或安慰剂(n=40),采用临床痴呆评定量表、神经心理学测试、脑脊液生物标志物、β-淀粉样蛋白正电子发射断层扫描和磁共振成像监测ARIA,并进行横断面和纵向分析。

主要发现

  • 初始225 mg/月甘特尼单抗剂量下未观察到ARIA-E,多数病例见于剂量>675 mg时;首次发生ARIA-E时全部受试者为淀粉样蛋白PET阳性,60%临床痴呆评定量表>0,60%已超过估计的症状出现年份,60%同时出现新发ARIA-H。
  • 多数ARIA-E在调整剂量后影像学消退,发生ARIA-E未显著增加试验中止的几率;ARIA-E更常见于枕叶(90%);ARIA-E严重程度与发生ARIA-E时的年龄相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the characteristics of participants with amyloid-related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD). METHODS: 142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β-amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross-sectional and longitudinal analyses evaluated potential ARIA-related risk factors. RESULTS: Eleven participants developed ARIA-E, including 3 with mild symptoms. No ARIA-E was reported under solanezumab while gantenerumab was associated with ARIA-E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE-ɛ4 carriers were more likely to develop ARIA-E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA-E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA-E occurrence, all ARIA-E participants were amyloid-PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA-H. Most ARIA-E radiologically resolved after dose adjustment and developing ARIA-E did not significantly increase odds of trial discontinuation. ARIA-E was more frequently observed in the occipital lobe (90%). ARIA-E severity was associated with age at time of ARIA-E. INTERPRETATION: In DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA-E risk, with additional risk for individuals APOE-ɛ4(+) or with microhemorrhage. ARIA-E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729-744.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Joseph-Mathurin N, Llibre-Guerra JJ, Li Y, et al. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Ann Neurol. 2022. PMID: 36151869. doi:10.1002/ana.26511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。